{
    "eid": "2-s2.0-84994091930",
    "title": "Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial",
    "cover-date": "2016-12-15",
    "subject-areas": [
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "cervical intraepithelial neoplasia",
        "clinical trial",
        "human papillomavirus vaccine",
        "treatment"
    ],
    "authors": [
        "Suzanne M. Garland"
    ],
    "citedby-count": 92,
    "ref-count": 40,
    "ref-list": [
        "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide",
        "Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication",
        "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study",
        "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
        "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women",
        "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases",
        "Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV Infection",
        "Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials",
        "Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women",
        "Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial",
        "Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a National Cancer Registry",
        "Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: Retrospective cohort study",
        "Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia",
        "Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: Population based cohort study",
        "Cervical intraepithelial neoplasia outcomes after treatment: Long-term follow-up from the british columbia cohort study",
        "Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: Population based cohort study",
        "Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR",
        "Efficacy and other milestones for human papillomavirus vaccine introduction",
        "Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2",
        "Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data",
        "Natural history of dysplasia of the uterine cervix",
        "The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice",
        "Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer",
        "Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?",
        "Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review",
        "Hybrid capture II testing for high-risk human papillomavirus DNA in the Follow-up of women treated for high-grade cervical intraepithelial neoplasia",
        "Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18",
        "Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection",
        "Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3",
        "Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study",
        "Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study",
        "Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation",
        "Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus",
        "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial",
        "HPV-FASTER: Broadening the scope for prevention of HPV-related cancer",
        "HPV vaccination: For women of all ages?",
        "EUROGIN 2010 roadmap on cervical cancer prevention",
        "Other potential indications and targets for HPV vaccination the case of mid-adult women"
    ],
    "affiliation": [
        {
            "affiliation-city": "Manila",
            "affilname": "University of the Philippines College of Medicine",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Philadelphia",
            "affilname": "GlaxoSmithKline, USA",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Leuven",
            "affilname": "KU Leuven\u2013 University Hospital Leuven",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Campinas",
            "affilname": "Universidade Estadual de Campinas",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Melbourne",
            "affilname": "University of Melbourne",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "The University of Sydney",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University College of Medicine",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Stiftung Juliusspital",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Helsinki",
            "affilname": "Vaestoliitto",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Curitiba",
            "affilname": "Universidade Federal do Parana",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Universitari de Bellvitge",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Tampere",
            "affilname": "Tampere University",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Mexico",
            "affilname": "Instituto Mexicano del Seguro Social",
            "affiliation-country": "Mexico"
        },
        {
            "affiliation-city": "Bardstown",
            "affilname": "Kentucky Pediatric/Adult Research",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Porto Alegre",
            "affilname": "Universidade Federal do Rio Grande do Sul",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Helsinki",
            "affilname": "Helsingin Yliopisto",
            "affiliation-country": "Finland"
        },
        {
            "affiliation-city": "Perth",
            "affilname": "The Kids Research Institute Australia",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Rixesart",
            "affilname": "GSK Vaccines",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Laguna",
            "affilname": "San Pablo Colleges Medical Center",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Hamburg",
            "affilname": "Facharzt f\u00fcr Frauenheilkunde und Geburtshilfe",
            "affiliation-country": "Germany"
        }
    ],
    "funding": []
}